Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma

Cancer Research

Volumn 66, Issue 13, 2006, Pages 6473-6476

  Chen, Yu Jen ^a   Hakin Smith, Vicky ^c   Teo, Mario ^c,h   Xinarianos, George E ^c,i   Jellinek, David A ^d   Carroll, Thomas ^d   McDowell, David ^b   MacFarlane, Martin R ^e   Boet, Ronald ^e   Baguley, Bruce C ^f   Braithwaite, Antony W ^a,g   Reddel, Roger R ^g   Royds, Janice A ^a,j  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b DUNEDIN HOSPITAL   (New Zealand)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^e CHRISTCHURCH HOSPITAL   (New Zealand)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^h GLASGOW ROYAL INFIRMARY   (United Kingdom)

ⁱ UNIVERSITY OF LIVERPOOL   (United Kingdom)

^j UNIVERSITY OF OTAGO   (New Zealand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; TELOMERASE;

ADULT; AGED; ARTICLE; CHROMOSOME SIZE; CONTROLLED STUDY; ENZYME ACTIVITY; EXON; FEMALE; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; TELOMERE; WILD TYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; TELOMERE;

EID: 33746136947     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0910     Document Type: Article

References (21)

1. Hakin-Smith V, Jellinek DA, Levy D, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003;361:836-8.
2. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995;14:4240-8.
3. Melean G, Sestini R, Ammannati F, Papi L. Genetic insights into familial tumors of the nervous system. Am J Med Genet C Semin Med Genet 2004;129:74-84.
4. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992;355:846-7.
5. Shiraishi S, Tada K, Nakamura H, et al. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 2002;95:249-57.
6. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001;61:1122-8.
7. Batchelor TT, Betensky RA, Esposito JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004;10:228-33.
8. Burton EC, Lamborn KR, Forsyth P, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002;8:180-7.
9. Rich JN, Hans C, Jones B, et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 2005;65:4051-8.
10. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-9.
11. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999;59:4175-9.
12. Xinarianos G, Liloglou T, Prime W, et al. p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma. Int J Cancer 2002;101:248-52.
13. Gross E, Kiechle M, Arnold N. Mutation analysis of p53 in ovarian tumors by DHPLC. J Biochem Biophys Methods 2001;47:73-81.
14. Kato H, Kato S, Kumabe T, et al. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 2000;6:3937-43.
15. Kakudo Y, Shibata H, Otsuka K, Kato S, Ishioka C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 2005;65:2108-14.
16. Royds JA, Hibma M, Dix BR, et al. p53 promotes adenoviral replication and increases late viral gene expression. Oncogene 2005;24:1-12.
17. Louis DN, von Deimling A, Chung RY, et al. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 1993;52:31-8.
18. Mekeel KL, Tang W, Kachnic LA, Luo CM, DeFrank JS, Powell SN. Inactivation of p53 results in high rates of homologous recombination. Oncogene 1997;14:1847-57.
19. Rogan EM, Bryan TM, Hukku B, et al. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 1995;15:4745-53.
20. Razak ZR, Varkonyi RJ, Kulp-McEliece M, et al. p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance. Mol Cell Biol 2004;24:5967-77.
21. Henson JD, Hannay JA, McCarthy SW, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005;11:217-25.